Shares of Albany Molecular Research Inc. (NASDAQ:AMRI) were up 4.6% during trading on Tuesday . The stock traded as high as $15.79 and last traded at $15.76, with a volume of 231,728 shares trading hands. The stock had previously closed at $15.06.

Separately, Morgan Stanley restated a “buy” rating and set a $17.00 price objective on shares of Albany Molecular Research in a research report on Friday, August 5th.

The stock’s market cap is $542.80 million. The company’s 50 day moving average is $14.86 and its 200 day moving average is $14.60.

Albany Molecular Research (NASDAQ:AMRI) last released its earnings results on Thursday, August 4th. The company reported $0.36 earnings per share for the quarter, topping the consensus estimate of $0.32 by $0.04. The company had revenue of $116.50 million for the quarter, compared to the consensus estimate of $123.10 million. Albany Molecular Research had a negative net margin of 7.37% and a positive return on equity of 3.17%. Analysts anticipate that Albany Molecular Research Inc. will post $1.09 earnings per share for the current fiscal year.

A number of hedge funds have recently added to or reduced their stakes in AMRI. BNP Paribas Arbitrage SA increased its stake in Albany Molecular Research by 116.1% in the second quarter. BNP Paribas Arbitrage SA now owns 8,329 shares of the company’s stock valued at $112,000 after buying an additional 4,475 shares in the last quarter. Dynamic Technology Lab Private Ltd acquired a new stake in Albany Molecular Research during the second quarter valued at approximately $145,000. Louisiana State Employees Retirement System increased its stake in Albany Molecular Research by 0.8% in the second quarter. Louisiana State Employees Retirement System now owns 12,000 shares of the company’s stock valued at $161,000 after buying an additional 100 shares during the period. State Board of Administration of Florida Retirement System increased its stake in Albany Molecular Research by 1.1% in the second quarter. State Board of Administration of Florida Retirement System now owns 12,318 shares of the company’s stock valued at $166,000 after buying an additional 140 shares during the period. Finally, BlackRock Advisors LLC increased its stake in Albany Molecular Research by 3.1% in the second quarter. BlackRock Advisors LLC now owns 12,382 shares of the company’s stock valued at $166,000 after buying an additional 374 shares during the period. 71.39% of the stock is currently owned by institutional investors.

Albany Molecular Research Company Profile

Albany Molecular Research, Inc is a global contract research and manufacturing company. The Company provides drug discovery, development, and manufacturing services. The Company operates through three segments: Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API) and Drug Product Manufacturing (DPM).

5 Day Chart for NASDAQ:AMRI

Receive News & Ratings for Albany Molecular Research Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albany Molecular Research Inc. and related companies with MarketBeat.com's FREE daily email newsletter.